Glenmark Pharmaceuticals has informed that it attached a media release today titled ‘Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe’.
The above information is a part of company’s filings submitted to BSE.